{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:28Z","timestamp":1786987588393,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":127,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101241","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:41:42Z","timestamp":1778283702000},"page":"101241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery"],"prefix":"10.1016","volume":"47","author":[{"given":"Makito","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Uenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101241_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101241_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101241_bib0003","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","article-title":"Radical cystectomy for bladder cancer today\u2014A homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101241_bib0004","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101241_bib0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9373","key":"10.1016\/j.ctarc.2026.101241_bib0006","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101241_bib0007","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3\u2013pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10232","key":"10.1016\/j.ctarc.2026.101241_bib0008","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101241_bib0009","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101241_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101241_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.07.011","article-title":"Real-world\u201d outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma","volume":"39","author":"Drakaki","year":"2021","journal-title":"Urol. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101241_bib0012","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"24009","key":"10.1016\/j.ctarc.2026.101241_bib0013","article-title":"A new electronic medical record database linked to claims data and discharge abstract data (the RWD database) in Japan: study design and profile","author":"Okumura","year":"2024","journal-title":"Ann. Clin. Epidemiol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101241_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.09.020","article-title":"Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan","volume":"43","author":"Yasuoka","year":"2025","journal-title":"Urol. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101241_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jgf2.367","article-title":"Data resource profile: JMDC claims databases sourced from Medical institutions","volume":"21","author":"Nagai","year":"2020","journal-title":"J. Gen. Fam. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101241_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2188\/jea.JE20200288","article-title":"History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan","volume":"31","author":"Hayashida","year":"2021","journal-title":"J. Epidemiol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101241_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70063","article-title":"Impact of early resumption of oral anticoagulation on recurrence after surgery for chronic subdural hematoma in patients with atrial fibrillation: a target trial emulation","volume":"33","author":"Anno","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101241_bib0018","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am. J. Kidney Dis."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101241_bib0019","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/aje\/kwac115","article-title":"A framework for descriptive epidemiology","volume":"191","author":"Lesko","year":"2022","journal-title":"Am. J. Epidemiol."},{"issue":"5_suppl","key":"10.1016\/j.ctarc.2026.101241_bib0020","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.2025.43.5_suppl.704","article-title":"Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy","volume":"43","author":"Squires","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101241_bib0021","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101241_bib0022","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101241_bib0023","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clgc.2021.10.002","article-title":"Discordance between clinical and pathological staging and grading in Upper Tract urothelial carcinoma","volume":"20","author":"Mori","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"issue":"13","key":"10.1016\/j.ctarc.2026.101241_bib0024","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1200\/JCO.23.02679","article-title":"Understanding adjuvant therapy for Upper Tract urothelial carcinoma","volume":"42","author":"Berg","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101241_bib0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11912-023-01390-9","article-title":"Current status of perioperative therapy in muscle-invasive bladder cancer and future directions","volume":"25","author":"Cockrell","year":"2023","journal-title":"Curr. Oncol. Rep."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:49:48Z","timestamp":1780919388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"alternative-id":["S2468294226001528"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101241","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101241"}}